NCT07178808 - PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 16, 2021

Primary Completion Date

February 22, 2026

Study Completion Date

February 22, 2031

Conditions

Gastric Adenocarcinoma

Interventions

PROCEDURE

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

CRS/HIPEC involves aggressive surgical cytoreduction of all visible and palpable tumors, followed by the synergistic use of heated and high dose chemotherapy to address microscopic residual disease.

Trial Locations (1)

85234

RECRUITING

Banner MD Anderson Cancer Center, Gilbert